SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the period ended January 6, 2003
Elan Corporation, plc
(Translation of registrant's name into English)
Lincoln House, Lincoln Place, Dublin 2, Ireland
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F /X/ Form 40-F / /
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes / / No /X/
This Report of Foreign Issuer on Form 6-K is incorporated by reference into
the Registration Statements on Form F-3 of Elan Corporation, plc (Registration
Nos. 333-10718, 333-10726 and 333-100252), the Registration Statement on Form
F-4 of Elan Corporation, plc and the Post-Effective Amendments thereto on Forms
F-3 and S-8 (No. 333-12756), the Registration Statement of Elan and Athena
Neuroscience Finance, LLC (No. 333-13130), and the Registration Statements on
Form S-8 of Elan Corporation, plc (Registration Nos. 333-13996, 333-12344,
333-11940, 333-09644, 333-09284, 333-09048, 333-08384, 333-07361, 333-07136,
333-14240, 33-27506 and 333-100556).
elan Corporate Bulletin
FOR IMMEDIATE RELEASE
CONTACTS:
INVESTORS: (U.S.) INVESTORS: (EUROPE) MEDIA:
Jack Howarth Emer Reynolds Sunny Uberoi
Ph: 212-407-5740 Ph: 353-1-709-4000 Ph: 212-994-8206
800-252-3526 00800 28352600 800-252-3526
ELAN NAMES G. KELLY MARTIN AS PRESIDENT AND
CHIEF EXECUTIVE OFFICER
GLOBAL BUSINESS EXECUTIVE TO LEAD NEW ELAN
Dublin, Ireland, January 6, 2003 - Elan Corporation, plc (NYSE:ELN) ("Elan")
today announced that G. Kelly Martin, 43, has been named President and Chief
Executive Officer of the company by unanimous vote of its Board of Directors.
The appointment is effective February 3, 2003.
"I am particularly pleased that Kelly possesses all the requirements which we
defined as critical for our CEO candidate. Although he does not have direct
pharmaceutical industry experience, Kelly's exceptional management and business
skills, along with his tremendous passion for what our company does, makes him
an outstanding choice to lead Elan in its efforts to recover and reestablish
itself as a leader in our industry," said Dr. Garo Armen, who will remain
Chairman of Elan.
Mr. Martin was a member of both the Executive Management and Operating Committee
of Merrill Lynch & Co. and was formerly president of the International Private
Client Group.
Mr. Martin's career at Merrill Lynch encompasses a broad array of operating and
executive responsibilities on a global basis. In his most recent position, he
was responsible for re-engineering the
company's non-US private client business. A critical success of this assignment
was achieving profitability for the first time in Japan.
Previously, Mr. Martin oversaw the overhaul of the Merrill's global debt markets
business after significant market turmoil in 1998. From 1995-1998, he was
responsible for systems and technology for Merrill Lynch. Earlier in his career
with Merrill Lynch, Mr. Martin spent eight years in London, and over two years
in Japan in a variety of roles. He received a B.A. degree in politics from
Princeton University in 1981.
"After more than 20 years on Wall Street and in the world's capital markets, I
am joining a company which has the opportunity to change the way diseases like
Alzheimer's, Crohn's and multiple sclerosis are treated," said Martin. "My goal
is to help bring these important compounds to market by ensuring a strong
financial future and operating platform for Elan."
Mr. Martin will join Elan's Board of Directors. As part of its continued
commitment to corporate governance, the company said the positions of Chief
Executive Officer and Chairman of the Board will be separate positions at Elan.
Elan is focused on the discovery, development, manufacturing, selling and
marketing of novel therapeutic products in neurology, pain management and
autoimmune diseases. Elan shares trade on the New York, London and Dublin Stock
Exchanges.
THIS NEWS RELEASE MAY CONTAIN CERTAIN FORWARD-LOOKING STATEMENTS BY ELAN THAT
INVOLVE RISKS AND UNCERTAINTIES AND REFLECT THE COMPANY'S JUDGMENT AS OF THE
DATE OF THIS RELEASE. ACTUAL EVENTS OR RESULTS MAY DIFFER FROM THE COMPANY'S
EXPECTATIONS. FURTHER RISKS, UNCERTAINTIES AND OTHER MATTERS CAN BE FOUND IN
ELAN'S ANNUAL REPORT ON FORM 20-F FOR THE FISCAL YEAR ENDED DECEMBER 31, 2001,
AND IN ITS REPORTS OF FOREIGN ISSUER ON FORM 6-K. ELAN ASSUMES NO OBLIGATION TO
UPDATE ANY FORWARD-LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION,
FUTURE EVENTS OR OTHERWISE.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ELAN CORPORATION, plc
By: /s/ William F. Daniel
---------------------------------------
William F. Daniel
Company Secretary
Date: January 7, 2003